Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
NUE heads into its October 26 earnings report with a familiar tension: the stock has bounced 5.4% this week to $246.44, yet the three months behind it show insiders selling heavily and analysts steadily marking down their targets.
The insider picture is the most concrete signal on offer. CEO Leon Topalian sold just over $7 million of stock on August 14 at prices around $268 to $269, through open-market transactions with no 10b5-1 plan disclosed. That sale was accompanied by an EVP (Allen Behr) selling a further $2.1 million the same day, and another EVP (Thomas Batterbee) selling $1 million in early August. Net insider activity over the past 90 days totals roughly -$17.3 million across -65,796 shares. None of these were pre-arranged plan sales, which makes the cluster harder to dismiss as routine.
The analyst community has been moving in the same direction, though less dramatically. The broad stance remains constructive: JP Morgan raised its target to $308 in September and multiple firms carry Overweight ratings, putting the mean target at $283.81 against a current price of $246.44. But the recent drift has been downward. Wells Fargo's Timna Tanners has cut her target twice since late August, most recently to $280. Keybanc trimmed to $286 this week while holding Overweight. Freedom Broker went further, downgrading to Hold with a $285 target in mid-September. The bulls still outnumber the bears on ratings, but targets have been creeping lower since the post-Q2 enthusiasm in late July, when Barclays, BMO and UBS all raised on the back of better-than-feared results.
Short positioning tells a quieter story and is not the lead angle here. Short interest runs at 1.85% of the free float, around 4.2 million shares, up roughly 19% over the past month but still very low in absolute terms. Borrow is cheap at 0.46%, even after jumping 26% this week. Availability is completely unconstricted, with more than 225 million shares available to lend relative to the shares already borrowed, the loosest conditions imaginable. Options positioning is also unremarkable: the put/call ratio at 0.81 sits just below its 20-day average of 0.82, with a z-score of -0.24. There is no squeeze pressure and no notable defensive hedging from the options market.
Valuation gives a mixed read. NUE trades at roughly 12.4x trailing earnings and 7.9x EV/EBITDA, both of which have compressed over the past 30 days. The PE multiple has fallen about 1.1 points over the month even as the price recovered from its October low, suggesting earnings estimates have moved more than the share price. Factor scores reflect that ambiguity: EPS momentum is strong over 30 and 90 days (ranked 72nd and 81st percentile respectively), but the forward EPS growth score sits at just the 28th percentile, a reminder that the Street is still modelling lower earnings year-on-year for the cycle ahead. The dividend score ranks in the 94th percentile, consistent with Nucor's long history of returning capital, though the most recent dividend data in the snapshot dates to 2022 and should not be taken as current.
One side note worth flagging: Wikipedia page views for Nucor spiked to a z-score of 2.69 against the stock's own 90-day history in late September, the highest retail attention reading in the period covered. That kind of search and page-view activity often tracks short-term price momentum rather than fundamental change, and with no measured alt-data lead for Nucor's financials in the ORTEX dataset, it is colour rather than signal.
Peers moved broadly in line this week. STLD gained 5.6%, CLF was the outperformer at 9.5%, while CMC and WS lagged, up 1.9% and 0.9% respectively. The sector-wide bounce keeps NUE from looking exceptional on the upside. The question heading into October 26 is whether the Q3 print can shift the narrative on forward earnings, or whether the insider selling and target cuts from recent weeks prove the more accurate read on the cycle.
See the live data behind this article on ORTEX.
Open NUE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.